Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05133492
Other study ID # CTP001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 24, 2019
Est. completion date December 31, 2026

Study information

Verified date January 2024
Source Nectero Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first in human study to evaluate the safety and clinical utility of an investigational medical device called the Nectero EAST System to treat Abdominal Aortic Aneurysms or AAA.


Description:

This is a Phase I multi-center, open-label study to evaluate use of the Nectero EAST system for stabilization of abdominal aortic aneurysms. Up to fifty (50) subjects will be treated at up to 10 worldwide sites with the device and followed for up to 36-months. Primary Study Endpoints: - Safety: absence of major events within the 1-month follow-up visit - Success: defined as successful insertion of the delivery catheter and delivery of the Stabilizer Secondary Study Endpoints: - Freedom from aneurysmal sac enlargement. Enlargement is defined as diameter increase of >5mm per year, or aneurysm sac volume increase of >10% per year, as assessed by CT scans at the 1, 3, (HK only), 6, 12, 24 and 36-month follow-up visits. - Aneurysm sac shrinkage, defined as diameter decrease of >5mm, or decrease in aneurysm sac volume of >10% as assessed by CT scans at the 1, 3 (HK only), 6, 12, 24 and 36-month follow-up visits. - Assessment of Clinical Utility Study duration is anticipated to be 6 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 46
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or Female aged 18 years or older - Subject can understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent and is willing to complete the follow-up according to the requirements of the protocol. - Infrarenal non-aneurysmal neck =15mm in length - Aortic neck diameters = 29mm - Infrarenal neck angulation = 60° - Abdominal aneurysm from 3.5 cm to 5.0 cm. - Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 10 cm - Patient iliac or femoral arteries access vessels' size and morphology allow endovascular access of 14F introducer sheaths and catheters. - Subject has > one-year life expectancy. - Subject is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive. - Subject is able and willing to comply with 1, 3, 6, 12, 24 and 36-month follow-up. Exclusion Criteria: - Subject has an acutely ruptured or leaking or emergent aneurysm. - Subject has a dissecting aneurysm. - Subject has a mycotic or infected aneurysm. - Subject has current vascular injury due to trauma. - Subject's aneurysm is thoracic or suprarenal. - Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm. - Subject has thrombus, calcification, and/or plaque that may compromise delivery. - Subject has had a myocardial infarction within six (6) months prior to enrollment. - Subject has current angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia, or valvular disease. - Subject has undergone other major surgery within the 30 days prior to enrollment. - Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months. - Known allergy to polyester or contrast material that cannot be pretreated. - Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta. - Subject has connective tissue disease (e.g., Marfan syndrome, Eaton syndrome, or Bessel's disease). - Known contraindication to undergoing angiography or anticoagulation. - Subject has active systemic infection. - Subject is participating in another research study. - Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment. - Women of childbearing potential who are pregnant, lactating, or planning to become pregnant during the course of the trial. - Subject has dialysis dependent renal failure or baseline serum creatinine level >2.0mg/dl. - Subjects with liver dysfunction: alanine transaminase (ALT) or aspartate transaminase (AST) is five times higher than the normal upper limit; serum total bilirubin (STB) is two times higher than the normal upper limit. - Subjects who are not suitable for endovascular treatment, as judged by the investigator.

Study Design


Intervention

Device:
Endovascular Aneurysm Stabilization Treatment (EAST)
Endovascular procedure: an ipsilateral ilio-femoral aortogram to confirm suitability for placement of a 14F sheath will be performed. A baseline contrast aortogram will be performed to assess vessel patency and target location of the EAST delivery catheter. Occluding and Stabilizer balloons are inflated in preparation for Stabilizer Compound delivery within the AAA sac. A post-Stabilizer angiogram will re-assess vessel patency and aorta stability. Delivery catheter is removed and discarded. The entire procedure is approximately one hour.

Locations

Country Name City State
Australia Prince of Wales Private Hospital Randwick New South Wales
China Queen Mary Hospital Hong Kong Southern District
Colombia Pablo Tabon Uribe Hospital Medellín Antioquia
New Zealand Auckland City Hospital Auckland

Sponsors (1)

Lead Sponsor Collaborator
Nectero Medical, Inc.

Countries where clinical trial is conducted

Australia,  China,  Colombia,  New Zealand, 

References & Publications (1)

Cheng SWK, Eagleton M, Echeverri S, Munoz JG, Holden AH, Hill AA, Krievins D, Ramaiah V. A pilot study to evaluate a novel localized treatment to stabilize small- to medium-sized infrarenal abdominal aortic aneurysms. J Vasc Surg. 2023 Oct;78(4):929-935.e1. doi: 10.1016/j.jvs.2023.05.056. Epub 2023 Jun 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: Procedure and Device-Related Adverse Events Absence of major events (procedure and device-related) within the 1-month follow-up visit Up to 30 days
Primary Efficacy: Successful delivery of the EAST System into the AAA sac Successful insertion of the delivery catheter and delivery of the Stabilizer Compound Up to 30 days
Secondary Efficacy: Evaluation of the AAA sac diameter over the 36 month follow up period. Freedom from aneurysmal sac enlargement. Enlargement is defined as diameter increase of >5mm per year, or aneurysm sac volume increase of >10% per year, as assessed by CT scans at the 1, 3, (HK only), 6, 12, 24 and 36-month follow-up visits. Through study completion, an average of 3 years
Secondary Efficacy: Evaluation of the AAA sac shrinkage over the 36 month follow up period. Aneurysm sac shrinkage, defined as diameter decrease of >5mm, or decrease in aneurysm sac volume of >10% as assessed by CT scans at the 1, 3 (HK only), 6, 12, 24 and 36-month follow-up visits. Through study completion, an average of 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04227054 - Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks N/A
Active, not recruiting NCT03687489 - Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System N/A
Active, not recruiting NCT03507413 - Metformin Therapy in Non-diabetic AAA Patients Phase 2/Phase 3
Not yet recruiting NCT05756283 - The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair N/A
Not yet recruiting NCT04089241 - Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair N/A
Active, not recruiting NCT02604303 - A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
Completed NCT02229006 - Sodium Fluoride Imaging of Abdominal Aortic Aneurysms N/A
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Terminated NCT01843335 - Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair N/A
Completed NCT02224794 - LIFE Study: Least Invasive Fast-Track EVAR
Terminated NCT01425242 - Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension N/A
Completed NCT01118520 - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) Phase 2
Completed NCT00746122 - Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair N/A
Completed NCT03952780 - Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
Completed NCT00583414 - Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients N/A
Recruiting NCT05864560 - Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
Completed NCT01683084 - Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms Phase 4
Active, not recruiting NCT03180996 - Global Fenestrated Anaconda Clinical sTudy
Completed NCT02493296 - The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
Completed NCT03320408 - Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers